NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

That's great information. Thank you always for your diligence, and specifically providing Dr. Liau's presentation slides this time.

It's great information because despite obvious absence of any Phase 3 DCVax-L trial mentioning, the whole thought process of Dr. Liau in the form of her presentation slides is actually what we are expecting for the analyses of DCVax-L trial presentation in the near future. [anybody can draw the curves of DCVax-L and fit it in the slide graphs. Wow beautifully superior!]

There are some specifics on how to present the control patients from comparable, contemporaneous trials as comparison with DCVax-L treatment from the presentation.

Once again, it's almost 100% certain at least both the primary endpoint and the first secondary endpoint of DCVax-L trial will be significant, and people will be able to understand how these comparative curves are prepared from what sorts of comparable representative data.

Highly informative and positively suggestive. Thanks again.